secwatch.observer — SEC 8-K summary
======================================

Issuer:     VivoSim Labs, INC. (VIVS)
CIK:        0001497253
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-045740
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organovo closes FXR program sale to Lilly; expects reduced spend and runway into FY2026
--------------------------------------------------------------------------------

- FXR program sold to Lilly; upfront payments received with future milestone payments anticipated.
- Overall expenditures expected to decrease due to elimination of FXR-related clinical, regulatory, and IP costs.
- Cash runway projected through end of FY2026; additional milestone payments could extend runway.
- Plans to leverage 3D human cellular IBD models to replicate FXR success with another therapeutic opportunity.
- Full-year FY2025 financial results expected on or about June 6-10, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025045740/0000950170-25-045740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1497253/000095017025045740/onvo-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-045740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer